๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chronic Lymphocytic Leukemia
Clinical trial register · Canada

Chronic Lymphocytic Leukemia Trials in Canada, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 6540 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:55 UTC
6540
Studies in scope
all four open statuses
3515
Recruiting now
open to new participants
887
Lead sponsors
across recruiting studies
Top sites
Montreal 12 Ottawa 9 Vancouver 8 Winnipeg 8 Toronto 8
Narrow the registerReset
Recruitment status
Phase
Site location
Montreal12 Ottawa9 Vancouver8 Winnipeg8 Toronto8
All 28 locations
Target enrolment
to

Chronic Lymphocytic Leukemia trials in Canada

21 of 6540 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Eli Lilly and Company
Phase 4
150
Toronto
2026-03-09
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Victoria, Hamilton, Montreal, Quรฉbec, Sherbrooke
2026-01-22
Not yet open
Time Restricted Eating in Haematological Malignancies
NCT06862323Cancer, Chronic Lymphocytic Leukemia
British Columbia Cancer Agency
Phase 2
75
Victoria
2025-06
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 2
249
Barrie, Saskatoon
2025-01-03
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Kelowna, Victoria, Brampton, Ottawa, Montreal, Rimouski
2023-12-13
Recruiting
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
NCT05371808Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Canadian Cancer Trials Group
Observational
247
Vancouver, Winnipeg, Saint John, Oshawa, Ottawa, Montreal
2023-01-27
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
737
Montreal, Quรฉbec, Winnipeg
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Vancouver, Moncton, Halifax, London, Toronto, Montreal, Regina
2022-07-21
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Calgary, Edmonton, Montreal, Toronto, Vancouver, Winnipeg
2021-09-20
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3
247
Vancouver, Winnipeg, Saint John, Halifax, Oshawa, Ottawa, Montreal, Regina
2021-03-02
Recruiting
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
NCT03765177Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Ottawa Hospital Research Institute
Phase 1/2
60
Vancouver, Winnipeg, Ottawa
2019-10-16
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
Quรฉbec
2019-09-06
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
984
Calgary, Edmonton, Vancouver, Ottawa, Toronto, Montreal, Quรฉbec
2019-02-25
Active, closed
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
310
Barrie, Calgary, Montreal, Ottawa, Regina, Saint John, Toronto
2017-02-02
Active, closed
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naรฏve CLL
NCT02475681Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
535
Vancouver, Halifax, Quรฉbec, Saint John, Winnipeg
2015-06-26
Active, closed
Economic Analysis of Alliance A041202 CLL Study
NCT02414022Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Observational
55
Calgary, Moncton, Greater Sudbury, Hamilton, Kingston, London, Newmarket, Ottawa
2015-04-15
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Montreal
2013-09-09
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-canada/condition/chronic-lymphocytic-leukemia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,540 studies in total at the last sync on 26 Sep 2026, 19:55 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies listing the condition Chronic Lymphocytic Leukemia.

How many Chronic Lymphocytic Leukemia trials are recruiting in Canada?

11 of the 21 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:55 UTC sync. A further 1 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chronic Lymphocytic Leukemia), 21 studies
PhaseStudiesRecruitingShare
Phase 313761.9%
Phase 23114.3%
Observational219.5%
Phase 1104.8%
Phase 1/2114.8%
Phase 4114.8%

Most active sponsors

Lead sponsors with the most studies (Chronic Lymphocytic Leukemia)
Lead sponsorStudiesRecruiting
Loxo Oncology, Inc.42
Acerta Pharma BV30
BeOne Medicines33
AbbVie20
Canadian Cancer Trials Group21
Merck Sharp & Dohme LLC21
British Columbia Cancer Agency10
Eli Lilly and Company11
Janssen Research & Development, LLC11
National Cancer Institute (NCI)11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.